Arcutis Q2 revenue rises on demand for ZORYVE, lifts 2026 sales outlook
ARQT•Commercial and access initiatives
Arcutis said it launched a virtual health platform and partnered with an AI-enabled healthcare provider to help facilitate access to ZORYVE.
The company also said it completed hiring of a targeted sales team for primary care and pediatric providers to support ZORYVE commercialization.
FDA approved an expanded indication for ZORYVE cream for children with plaque psoriasis.
Q2 revenue rises on ZORYVE demand
Arcutis said second-quarter product revenue rose 59% year over year, driven by demand for ZORYVE products.
The company reported:
| Metric | Actual |
|---|---|
| Q2 Product Revenue | $129.86 million |
| Q2 EPS | $0.11 |
| Q2 Net Income | $15.009 million |
| Q2 Operating Expenses | $113.43 million |
| Q2 Operating Income | $16.43 million |
Arcutis said revenue growth was primarily driven by increased demand for ZORYVE products.
2026 sales outlook raised
Arcutis raised its 2026 full-year net product sales guidance to $525 million–$540 million.
The company also said it expects topline results for its Phase 2 vitiligo study in the fourth quarter of 2026.
FDA set a target action date of for the ZORYVE cream 0.05% sNDA.
Related News
Barings BDC Q2 FY26 net investment income rises to $29 million; NAV per share slips to $10.94
TriplePoint Venture Growth Q2 net investment income falls on higher interest costs
